Sign in or create an account to add this stock to your watchlist.
About Exelixis (NASDAQ:EXEL)
Exelixis, Inc., a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. It also offers COTELLIC tablets, an inhibitor of MEK in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreement with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, Daiichi Sankyo Company Limited, and Invenra, Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:EXEL
CUSIP30161Q10
Phone650-837-7000
Debt
Debt-to-Equity RatioN/A
Current Ratio6.67
Quick Ratio6.58
Price-To-Earnings
Trailing P/E Ratio40.86
Forward P/E Ratio24.23
P/E Growth0.53
Sales & Book Value
Annual Sales$452.48 million
Price / Sales13.67
Cash Flow$0.5470 per share
Price / Cash38.10
Book Value$2.26 per share
Price / Book9.22
Profitability
EPS (Most Recent Fiscal Year)$0.51
Net Income$154.22 million
Net Margins43.39%
Return on Equity77.39%
Return on Assets40.62%
Miscellaneous
Employees372
Outstanding Shares296,870,000
Exelixis (NASDAQ:EXEL) Frequently Asked Questions
What is Exelixis' stock symbol?
Exelixis trades on the NASDAQ under the ticker symbol "EXEL."
How were Exelixis' earnings last quarter?
Exelixis, Inc. (NASDAQ:EXEL) released its quarterly earnings data on Wednesday, May, 2nd. The biotechnology company reported $0.37 EPS for the quarter, beating the Zacks' consensus estimate of $0.16 by $0.21. The biotechnology company earned $212.35 million during the quarter, compared to the consensus estimate of $146.39 million. Exelixis had a net margin of 43.39% and a return on equity of 77.39%. View Exelixis' Earnings History.
What price target have analysts set for EXEL?
12 brokers have issued 1-year price targets for Exelixis' shares. Their predictions range from $28.00 to $40.00. On average, they expect Exelixis' stock price to reach $33.5556 in the next year. View Analyst Ratings for Exelixis.
What are Wall Street analysts saying about Exelixis stock?
Here are some recent quotes from research analysts about Exelixis stock:
- 1. Cann analysts commented, "Numerous presentations for Cabometyx are expected at 2018 ASCO and abstracts for these were released last night. There are multiple presentations on the previously released CELESTIAL randomized pivotal phase III trial of Cabometyx in patients with advanced HCC. In addition to the CELESTIAL data presentations, we believe the Cabometyx in combination with checkpoint inhibitors in urothelial cancer and Cometriq in metastatic Thyroid cancer are of interest." (5/17/2018)
- 2. According to Zacks Investment Research, "Exelixis’ first-quarter results were impressive wherein both earnings and sales beat estimates by a wide margin. Demand for Cabometyx grew by approximately 30% sequentially driven by increases in new patient starts and refills for patients already on therapy. We expect sales to get a further boost in 2018 as the drug is now approved for first-line RCC which will increases the eligible patient population for Caobometyx in the United States by approximately 14,000 patients and grab market share from two key drugs — Sutent and Votrient in the first-line RCC market. A potential label expansion for advanced HCC will further boost the growth prospects of the company. However, competition has further stiffened up with the recent approval of Opdivo and Yervoy for the treatment of poor and intermediate risk first-line RCC. A label expansion of Cotellic will also boost the sales. Shares have outperformed the industry in the last twelve months." (5/15/2018)
Are investors shorting Exelixis?
Exelixis saw a decrease in short interest in the month of April. As of April 30th, there was short interest totalling 9,345,969 shares, a decrease of 27.4% from the April 13th total of 12,873,448 shares. Based on an average daily volume of 2,396,338 shares, the short-interest ratio is presently 3.9 days. Currently, 3.3% of the company's stock are short sold.
Who are some of Exelixis' key competitors?
Some companies that are related to Exelixis include IQVIA (IQV), Incyte (INCY), Icon (ICLR), EXACT Sciences (EXAS), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), BTG (BTGGF), Intrexon (XON), Medpace (MEDP), National Research (NRCIB), National Research (NRCIA), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS) and Eloxx Pharmaceuticals (ELOX).
Who are Exelixis' key executives?
Exelixis' management team includes the folowing people:
- Dr. Stelios Papadopoulos, Co-Founder & Chairman (Age 70)
- Dr. Michael M. Morrissey, CEO, Pres & Director (Age 57)
- Mr. Christopher J. Senner, Exec. VP & CFO (Age 50)
- Dr. Peter Lamb, Exec. VP of Scientific Strategy & Chief Scientific Officer (Age 57)
- Mr. Jeffrey J. Hessekiel, Exec. VP, Gen. Counsel & Sec. (Age 49)
Has Exelixis been receiving favorable news coverage?
Media headlines about EXEL stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Exelixis earned a coverage optimism score of 0.08 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 46.31 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
Who are Exelixis' major shareholders?
Exelixis' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.49%), JPMorgan Chase & Co. (1.70%), Wells Fargo & Company MN (1.29%), Old Mutual Global Investors UK Ltd. (1.20%), Franklin Resources Inc. (0.72%) and OppenheimerFunds Inc. (0.50%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View Institutional Ownership Trends for Exelixis.
Which major investors are selling Exelixis stock?
EXEL stock was sold by a variety of institutional investors in the last quarter, including Blair William & Co. IL, American Century Companies Inc., Natixis, Franklin Resources Inc., KBC Group NV, Point72 Asset Management L.P., Seven Eight Capital LP and Chicago Equity Partners LLC. Company insiders that have sold Exelixis company stock in the last year include Alan M Garber, Charles Cohen, Christopher J Senner, George Poste, Gisela Schwab, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Stelios Papadopoulos and Vincent T Marchesi. View Insider Buying and Selling for Exelixis.
Which major investors are buying Exelixis stock?
EXEL stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Old Mutual Global Investors UK Ltd., Wells Fargo & Company MN, Neuberger Berman Group LLC, EULAV Asset Management, Chicago Capital LLC, Carillon Tower Advisers Inc. and UBS Group AG. View Insider Buying and Selling for Exelixis.
How do I buy shares of Exelixis?
Shares of EXEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Exelixis' stock price today?
One share of EXEL stock can currently be purchased for approximately $20.84.
How big of a company is Exelixis?
Exelixis has a market capitalization of $6.19 billion and generates $452.48 million in revenue each year. The biotechnology company earns $154.22 million in net income (profit) each year or $0.51 on an earnings per share basis. Exelixis employs 372 workers across the globe.
How can I contact Exelixis?
Exelixis' mailing address is 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-837-7000 or via email at [email protected]
MarketBeat Community Rating for Exelixis (EXEL)
MarketBeat's community ratings are surveys of what our community members think about Exelixis and other stocks. Vote "Outperform" if you believe EXEL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EXEL will underperform the S&P 500 over the long term. You may vote once every thirty days.
Exelixis (NASDAQ:EXEL) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
12 Wall Street analysts have issued ratings and price targets for Exelixis in the last 12 months. Their average twelve-month price target is $33.5556, suggesting that the stock has a possible upside of 61.02%. The high price target for EXEL is $40.00 and the low price target for EXEL is $28.00. There are currently 3 hold ratings and 9 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.75 | 2.75 | 2.50 | 2.50 |
| Ratings Breakdown: | 0 Sell Rating(s)
3 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
6 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
6 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $33.5556 | $34.00 | $31.7143 | $31.2857 |
| Price Target Upside: | 61.02% upside | 65.21% upside | 12.42% upside | 7.81% upside |
Exelixis (NASDAQ:EXEL) Consensus Price Target History
Exelixis (NASDAQ:EXEL) Analyst Ratings History
Show:
(Data available from 5/27/2016 forward)
Exelixis (NASDAQ:EXEL) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Exelixis (NASDAQ EXEL) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.80%
Institutional Ownership Percentage: 77.40%
Exelixis (NASDAQ EXEL) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/24/2018 | Michael Morrissey | Insider | Sell | 90,000 | $20.55 | $1,849,500.00 | |  |
| 5/22/2018 | Lance Willsey | Director | Sell | 50,000 | $21.40 | $1,070,000.00 | 418,273 | |
| 5/18/2018 | Patrick J. Haley | VP | Sell | 3,663 | $21.61 | $79,157.43 | | |
| 5/11/2018 | Vincent T. Marchesi | Director | Sell | 15,000 | $19.03 | $285,450.00 | | |
| 5/9/2018 | Charles Cohen | Director | Sell | 15,000 | $21.42 | $321,300.00 | 263,180 | |
| 5/7/2018 | Patrick J. Haley | Insider | Sell | 27,549 | $22.17 | $610,761.33 | | |
| 5/7/2018 | Stelios Papadopoulos | Director | Sell | 15,000 | $22.15 | $332,250.00 | | |
| 5/4/2018 | Jeffrey Hessekiel | EVP | Sell | 20,000 | $22.36 | $447,200.00 | | |
| 5/4/2018 | Patrick J. Haley | VP | Sell | 12,549 | $22.38 | $280,846.62 | | |
| 5/3/2018 | Gisela Schwab | CMO | Sell | 22,500 | $23.09 | $519,525.00 | | |
| 4/16/2018 | Alan M Garber | Director | Sell | 15,000 | $20.25 | $303,750.00 | 76,329 | |
| 4/11/2018 | Michael Morrissey | Insider | Sell | 90,000 | $20.78 | $1,870,200.00 | | |
| 3/6/2018 | Vincent T. Marchesi | Director | Sell | 15,000 | $24.73 | $370,950.00 | | |
| 3/2/2018 | Lance Willsey | Director | Sell | 30,000 | $23.91 | $717,300.00 | 483,273 | |
| 2/28/2018 | George Poste | Director | Sell | 15,000 | $26.26 | $393,900.00 | | |
| 2/28/2018 | Patrick J. Haley | VP | Sell | 45,029 | $27.13 | $1,221,636.77 | | |
| 1/9/2018 | Alan M Garber | Director | Sell | 15,000 | $30.30 | $454,500.00 | 64,829 | |
| 9/28/2017 | Gisela Schwab | Insider | Sell | 100,000 | $23.79 | $2,379,000.00 | | |
| 9/28/2017 | Jeffrey Hessekiel | EVP | Sell | 27,302 | $24.28 | $662,892.56 | | |
| 9/22/2017 | Stelios Papadopoulos | Director | Sell | 10,000 | $25.40 | $254,000.00 | | |
| 9/19/2017 | Stelios Papadopoulos | Director | Sell | 200,000 | $27.68 | $5,536,000.00 | | |
| 9/18/2017 | Stelios Papadopoulos | Director | Sell | 72,210 | $27.76 | $2,004,549.60 | | |
| 9/14/2017 | Michael Morrissey | Insider | Sell | 300,000 | $26.90 | $8,070,000.00 | | |
| 9/14/2017 | Patrick J. Haley | VP | Sell | 60,640 | $27.21 | $1,650,014.40 | | |
| 9/13/2017 | Lance Willsey | Director | Sell | 100,000 | $26.88 | $2,688,000.00 | 518,273 | |
| 9/12/2017 | Christopher J. Senner | CFO | Sell | 100,000 | $26.79 | $2,679,000.00 | | |
| 5/30/2017 | Patrick J. Haley | Insider | Sell | 5,000 | $18.46 | $92,300.00 | | |
| 5/15/2017 | Carl B Feldbaum | Director | Sell | 32,988 | $21.58 | $711,881.04 | 52,721 | |
| 5/10/2017 | Michael Morrissey | Insider | Sell | 211,300 | $21.87 | $4,621,131.00 | | |
| 5/9/2017 | Michael Morrissey | CEO | Sell | 100,000 | $21.69 | $2,169,000.00 | | |
| 5/8/2017 | Michael Morrissey | CEO | Sell | 11,300 | $21.81 | $246,453.00 | | |
| 5/5/2017 | Michael Morrissey | Insider | Sell | 259,149 | $22.24 | $5,763,473.76 | | |
| 5/1/2017 | Gisela Schwab | CMO | Sell | 89,910 | $23.01 | $2,068,829.10 | | |
| 4/3/2017 | Vincent T Marchesi | Director | Sell | 10,000 | $21.30 | $213,000.00 | 130,070 | |
| 3/31/2017 | Jack L Wyszomierski | Director | Sell | 5,150 | $21.57 | $111,085.50 | 78,110 | |
| 3/27/2017 | Jeffrey Hessekiel | EVP | Sell | 6,884 | $21.02 | $144,701.68 | | |
| 3/22/2017 | Jeffrey Hessekiel | EVP | Sell | 23,787 | $20.54 | $488,584.98 | | |
| 3/20/2017 | Stelios Papadopoulos | Director | Sell | 10,000 | $21.66 | $216,600.00 | 1,238,471 | |
| 3/13/2017 | Charles Cohen | Director | Sell | 10,000 | $21.82 | $218,200.00 | 238,180 | |
| 3/10/2017 | Vincent T Marchesi | Director | Sell | 40,000 | $21.98 | $879,200.00 | 160,070 | |
| 3/6/2017 | Michael Morrissey | Insider | Sell | 200,000 | $22.72 | $4,544,000.00 | | |
| 3/3/2017 | Christopher J. Senner | CFO | Sell | 11,000 | $22.80 | $250,800.00 | | |
| 3/2/2017 | George Poste | Director | Sell | 76,250 | $22.53 | $1,717,912.50 | 86,405 | |
| 1/3/2017 | Peter Lamb | EVP | Sell | 70,000 | $14.65 | $1,025,500.00 | | |
| 12/16/2016 | Carl B. Feldbaum | Director | Sell | 25,000 | $17.03 | $425,750.00 | | |
| 12/9/2016 | Alan M. Garber | Director | Sell | 7,832 | $16.90 | $132,360.80 | | |
| 12/7/2016 | George A. Scangos | Director | Sell | 204,894 | $17.81 | $3,649,162.14 | | |
| 12/5/2016 | George A. Scangos | Director | Sell | 204,718 | $17.81 | $3,646,027.58 | | |
| 12/1/2016 | Gisela Schwab | Insider | Sell | 22,000 | $16.73 | $368,060.00 | | |
| 12/1/2016 | Peter Lamb | EVP | Sell | 70,000 | $16.66 | $1,166,200.00 | | |
| 8/4/2016 | Gisela Schwab | Insider | Sell | 42,338 | $11.00 | $465,718.00 | 174,354 | |
| 5/11/2016 | Lance Willsey | Director | Buy | 60,000 | $4.97 | $298,200.00 | 548,273 | |
| 5/9/2016 | Lance Willsey | Director | Buy | 40,000 | $4.97 | $198,800.00 | 548,273 | |
| 12/11/2015 | Lance Willsey | Director | Buy | 100,000 | $4.89 | $489,000.00 | 494,975 | |
| 10/16/2015 | Peter Lamb | EVP | Sell | 51,549 | $5.80 | $298,984.20 | 36,473 | |
| 10/13/2015 | Peter Lamb | EVP | Sell | 600 | $5.80 | $3,480.00 | 36,473 | |
| 10/12/2015 | Peter Lamb | EVP | Sell | 300,276 | $5.84 | $1,753,611.84 | 36,473 | |
| 9/17/2014 | Vincent T Marchesi | Director | Buy | 20,000 | $1.71 | $34,200.00 | | |
| 8/29/2013 | Lance Willsey | Director | Buy | 10,000 | $5.15 | $51,500.00 | 333,700 | |
| 12/20/2012 | Vincent T Marchesi | Director | Buy | 4,000 | $4.68 | $18,720.00 | | |
| 12/19/2012 | Vincent T Marchesi | Director | Buy | 6,000 | $4.72 | $28,320.00 | | |
| 12/10/2012 | Gisela Schwab | EVP | Buy | 25,000 | $4.39 | $109,750.00 | | |
(Data available from 1/1/2013 forward)
Exelixis (NASDAQ EXEL) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Opdivo Continues to Be Key Growth Driver for Bristol-Myers Squibb
finance.yahoo.com - May 25 at 3:13 PM |
 | Michael Morrissey Sells 90,000 Shares of Exelixis, Inc. (EXEL) Stock
www.americanbankingnews.com - May 24 at 10:10 PM |
| Exelixis, Inc. (EXEL) Director Sells $1,070,000.00 in Stock
www.americanbankingnews.com - May 24 at 10:10 PM |
 | Ovarian Cancer Drugs Market Latest Industry Scenario, Trends, Share & Future Forecast By 2022
www.marketwatch.com - May 24 at 3:14 PM |
 | Mining For ASCO 2018's Gold, Part 2: Some Studies Trend Toward Negative
seekingalpha.com - May 24 at 3:14 PM |
 | Biotech Stock Roundup: FDA Gives Nod to Amgen's Drugs, EU Approves Exelixis' Cabometyx
www.zacks.com - May 23 at 3:01 PM |
| Today's Research Reports on Trending Tickers: Tesaro and Exelixis
finance.yahoo.com - May 23 at 3:01 PM |
 | BRIEF-Exelixis Appoints Andrew Peters To Newly Created Position Of Vice President, Strategy
www.reuters.com - May 23 at 5:16 AM |
| Exelixis Appoints Andrew R. Peters to Newly Created Position of Vice President, Strategy
finance.yahoo.com - May 23 at 5:16 AM |
| National Research (NRCIB) and Exelixis (EXEL) Head to Head Review
www.americanbankingnews.com - May 18 at 11:24 PM |
| Patrick J. Haley Sells 3,663 Shares of Exelixis (EXEL) Stock
www.americanbankingnews.com - May 18 at 10:16 PM |
| This May Be The Best Time To Pick Up Exelixis In 2018
seekingalpha.com - May 18 at 3:08 PM |
 | Trade of the Day: Exelixis, Inc. (EXEL)
investorplace.com - May 18 at 9:28 AM |
| Exelixis: Temporary Concern Of Cobimetinib Created A Stellar Buying Opportunity
seekingalpha.com - May 18 at 5:05 AM |
| Exelixis (EXEL) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - May 17 at 10:54 PM |
 | Oppenheimer Reiterates Outperform on Exelixis (EXEL)
www.streetinsider.com - May 17 at 3:11 PM |
| Exelixis' Cabometyx Gets EU Nod for First-Line Kidney Cancer
www.zacks.com - May 17 at 3:11 PM |
| Exelixis Focused on Positioning Cabometyx in Kidney Cancer Space
finance.yahoo.com - May 17 at 3:11 PM |
| Exelixis (EXEL) Earns "Buy" Rating from Cann
www.americanbankingnews.com - May 17 at 2:51 PM |
 | Exelixis To Get $50 Mln As Ipsen Gets Expanded EC Approval For CABOMETYX
www.nasdaq.com - May 17 at 5:48 AM |
| Reader Inquiry: Will Core Biotech Holding Exelixis Rebound?
seekingalpha.com - May 16 at 3:16 PM |
| Are Options Traders Betting on a Big Move in Exelixis (EXEL) Stock?
finance.yahoo.com - May 16 at 3:16 PM |
| Exelixis (EXEL) Upgraded at BidaskClub
www.americanbankingnews.com - May 16 at 11:05 AM |
| Zacks Investment Research Lowers Exelixis (EXEL) to Hold
www.americanbankingnews.com - May 15 at 1:13 PM |
| Exelixis: Time To Excel
seekingalpha.com - May 14 at 5:13 AM |
| Exelixis Will Continue It's Stride Despite Cotellic Combo Failure In Colorectal Cancer
seekingalpha.com - May 14 at 5:13 AM |
| FY2022 Earnings Estimate for Exelixis Issued By SunTrust Banks (EXEL)
www.americanbankingnews.com - May 14 at 5:05 AM |
| Exelixis (EXEL) Expected to Post Quarterly Sales of $151.02 Million
www.americanbankingnews.com - May 13 at 4:15 AM |
| Lucky Seven: Omeros Pops, Exelixis Drops On Phase 3 Flop
seekingalpha.com - May 12 at 7:25 AM |
| Trump Announces Plan to Reign In Drug Prices and Pharma Stocks Rally.
finance.yahoo.com - May 12 at 7:25 AM |
| Exelixis (EXEL) Short Interest Update
www.americanbankingnews.com - May 12 at 2:10 AM |
| Insider Selling: Exelixis (EXEL) Director Sells 15,000 Shares of Stock
www.americanbankingnews.com - May 11 at 10:21 PM |
| ValuEngine Downgrades Exelixis (EXEL) to Strong Sell
www.americanbankingnews.com - May 11 at 9:23 PM |
| Needham & Company LLC Cuts Exelixis (EXEL) Price Target to $30.00
www.americanbankingnews.com - May 11 at 7:49 PM |
| Exelixis (EXEL) Expected to Post Earnings of $0.14 Per Share
www.americanbankingnews.com - May 11 at 3:25 PM |
| Bull of the Day: Exelixis (EXEL)
www.zacks.com - May 11 at 3:20 PM |
| Lenvima Is Expected to Boost Merck’s Oncology Portfolio in 2018
finance.yahoo.com - May 11 at 3:20 PM |
| Exelixis: Elucidating The Recent Developments Powering A Big Winner
seekingalpha.com - May 11 at 5:20 AM |
| Exelixis (EXEL) Director Sells $321,300.00 in Stock
www.americanbankingnews.com - May 10 at 10:15 PM |
| Exelixis (EXEL) PT Lowered to $35 at RBC Capital, Remains Bullish
www.streetinsider.com - May 10 at 3:10 PM |
| Why Exelixis Dropped Today
finance.yahoo.com - May 10 at 3:10 PM |
| Piper Jaffray Lowers Exelixis (EXEL) Price Target to $29.00
www.americanbankingnews.com - May 10 at 1:28 PM |
| BRIEF-Exelixis Says Phase 3 Imblaze370 Study Did Not Meet Its Primary Endpoint Of Improving Overall Survival Vs ...
www.reuters.com - May 10 at 5:01 AM |
 | Exelixis Provides Update on IMblaze370 Phase 3 Pivotal Trial of Atezolizumab and Cobimetinib in Patients With ...
www.businesswire.com - May 10 at 5:01 AM |
| Exelixis to Present at the Bank of America Merrill Lynch Health Care Conference on May 15, 2018
finance.yahoo.com - May 9 at 5:10 AM |
| Exelixis (EXEL) Lifted to Strong-Buy at Zacks Investment Research
www.americanbankingnews.com - May 8 at 3:23 PM |
| Intercept (ICPT) Q1 Loss Narrower Than Expected, Sales Lag
finance.yahoo.com - May 8 at 3:02 PM |
| Insider Selling: Exelixis (EXEL) VP Sells 12,549 Shares of Stock
www.americanbankingnews.com - May 7 at 10:26 PM |
| Exelixis (EXEL) Director Stelios Papadopoulos Sells 15,000 Shares
www.americanbankingnews.com - May 7 at 10:26 PM |
| Exelixis (EXEL) EVP Sells $447,200.00 in Stock
www.americanbankingnews.com - May 7 at 10:26 PM |
Exelixis (NASDAQ:EXEL) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Exelixis (NASDAQ:EXEL) Income Statement, Balance Sheet and Cash Flow Statement
Exelixis (NASDAQ EXEL) Stock Chart for Sunday, May, 27, 2018
Loading chart…
